Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response‐adapted design in the first‐line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY)
Saved in:
| Title: | Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response‐adapted design in the first‐line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY) |
|---|---|
| Authors: | Gibb, Adam1 (AUTHOR), Pirrie, Sarah J.2 (AUTHOR), Linton, Kim1,3 (AUTHOR), Warbey, Victoria4 (AUTHOR), Paterson, Kathryn2 (AUTHOR), Davies, Andrew J.5 (AUTHOR), Collins, Graham P.6 (AUTHOR), Menne, Tobias7 (AUTHOR), McKay, Pamela8 (AUTHOR), Fields, Paul A.9 (AUTHOR), Miall, Fiona M.10 (AUTHOR), Nagy, Eszter2 (AUTHOR), Wheatley, Keith2 (AUTHOR), Reed, Rachel11 (AUTHOR), Baricevic‐Jones, Ivona11 (AUTHOR), Barrington, Sally4 (AUTHOR), Radford, John1,3 (AUTHOR) john.radford@manchester.ac.uk |
| Source: | British Journal of Haematology. Apr2021, Vol. 193 Issue 1, p63-71. 9p. |
| Database: | Academic Search Ultimate |
| ISSN: | 00071048 |
|---|---|
| DOI: | 10.1111/bjh.17073 |
